| Histopathologic alterations following local delivery of dexamethasone to inhibit restenosis in murine arteries. | |
| | |
MedLine Citation:
|
PMID: 16023630 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: Dexamethasone-eluting stents are currently under evaluation to prevent post-angioplasty restenosis. The efficacy and safety of dexamethasone as an anti-restenotic agent is still unclear. We assess the effect of perivascular delivery of dexamethasone on vascular pathology in a mouse model of restenosis. METHODS AND RESULTS: In this study we investigate the ability of both systemic and local dexamethasone treatment to inhibit neointima formation after cuff placement around C57BL/6 mouse femoral artery. As in the clinical situation, systemic dexamethasone treatment shows adverse side effects in animals, including weight loss. In contrast, local delivery of dexamethasone using a drug-eluting polymer cuff inhibits neointima formation and has no systemic adverse effects. Pathobiological examination of the experimental arteries, however, reveals a dose-dependent medial atrophy, a reduction in vascular smooth muscle cells and collagen content, an increase in apoptotic cell count and disruption of the internal elastic lamina. CONCLUSIONS: Our results demonstrate that although local dexamethasone delivery is effective as an inhibitor for neointima formation, it is dose-dependently associated with adverse vascular morphological changes pointing to a loss of vascular integrity. |
| | |
Authors:
|
Nuno M M Pires; Abbey Schepers; Barend L van der Hoeven; Margreet R de Vries; Lianne S M Boesten; J Wouter Jukema; Paul H A Quax |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2005-07-15 |
Journal Detail:
|
Title: Cardiovascular research Volume: 68 ISSN: 0008-6363 ISO Abbreviation: Cardiovasc. Res. Publication Date: 2005 Dec |
Date Detail:
|
Created Date: 2005-11-08 Completed Date: 2006-05-03 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0077427 Medline TA: Cardiovasc Res Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 415-24 Citation Subset: IM |
Affiliation:
|
TNO-Quality of Life, Gaubius Laboratory, Zernikedreef 9, 2333 CK Leiden, The Netherlands. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Angioplasty, Transluminal, Percutaneous Coronary Animals Anti-Inflammatory Agents / administration & dosage*, therapeutic use Apoptosis / drug effects Cell Proliferation / drug effects Collagen / analysis Coronary Disease / therapy Coronary Restenosis / prevention & control* Dexamethasone / administration & dosage*, therapeutic use Femoral Artery / pathology* Male Mice Mice, Inbred C57BL Models, Animal Muscle, Smooth, Vascular / pathology Stents* Tunica Intima / pathology* |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Inflammatory Agents; 50-02-2/Dexamethasone; 9007-34-5/Collagen |
| Comments/Corrections | |
Comment In:
|
Cardiovasc Res. 2005 Dec 1;68(3):350-2
[PMID:
16242679
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Syntheses of beta-(1-->6)-branched beta-(1-->3)-linked d-galactans that exist in the rhizomes of Atr...
Next Document: Formation of 8-nitroguanine in blood of patients with inflammatory gouty arthritis.